Test your cancer knowledge with CERI - take today's quiz, share with you friends!
This is our long-time game we've created, the CERI Cancer Quiz Game™!
Test your cancer knowledge with CERI - take today's quiz, share with you friends!
You can find the correct answer in two of our videos on our Youtube channel:
COME BACK EVERY WEDNESDAY FOR OUR 'QUESTION OF THE DAY' QUIZ!
By Ayguen Sahin, MSc, PhD - Cancer Education and Research Institute
In some cancers, cancer cells can invade in along nerves causing an aggressive perineural invasion (PNI, the invasion of cancer to the space surrounding a nerve), which leads to pain and paralysis, and reduced survival.
A study led by Deborde and colleagues showed that cancer cells exploit normal Schwann cell nerve repair programs to promote perineural invasion. This research study observed these results in:
Schwann cells are a type of glial cells, which surrounds neurons and play an essential role in the fuction and survival of the neurons.
Cancer cells formed protrusions and migration toward Schwann cells through a protein called NCAM1 (Neural Adhesion Molecule 1), which is correlated with the presence of perineural invasion.
Perineural invasion (PNI) is also often seen in:
🔊 Our patient from Turkey entered our CERI Personalized Patient Program™ and we are so happy that after her 'delayed' treatment in Turkey due to Covid-19 in 2020, her recent biopsy via VATS (Video Assisted Thoracic Surgery) here in Boston confirmed TODAY that she's officially CANCER-FREE!! WOOHOO! 👍👏💪🎊🎉
Pictures to follow! Stay tuned 👉 @canceredinstitute
Show your love to her in the comments below and we'll be sure to show them to her. 🙏❤️👏💪👍
To learn more about our CERI Personalized Patient Program™ visit:
100% of our completed cases, which includes patients with various cancer types, are to date still cancer-free! 👏💪
Please donate, so that we can save more lives! 🙏❤️
#lungcancer #nonsmallcelllungcancer #nsclc #lungcancerawareness #cancerfree #cancerpatient #cancersurvivor #cancertreatment #cancertreatmentworldwide #patientcare #patienteducation #patientguidance #wecanhelp #cancerpatientstories #cancerpatientprogram #yourenotalone #cancercareforall #cancertreatmentforall #qualityhealthcareforall #equalhealth #equalhealthcareforall
The US Food and Drug Administration (FDA) has approved lorlatinib for metastatic ALK-positive NSCLC
On March 3, 2021, the Food and Drug Administration granted regular approval to lorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive, detected by an FDA-approved test, Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.).
Lorlatinib received accelerated approval in November 2018 for the second- or third-line treatment of ALK-positive metastatic NSCLC.
This current approval is based on data from Study B7461006 (NCT03052608), a randomized, multicenter, open-label, active-controlled trial conducted in 296 patients with ALK-positive metastatic NSCLC who had not received prior systemic therapy for metastatic disease.
If you need help for your cancer treatment and care, apply to our CERI Personalized Patient Program™:
#NSCLC #nonsmallcelllungcancer #AKLpositive #AKLpositiveNSCLC #lorlatinib #Lorbrena #pfizer #cancertreatment #ventana #ALKtest #fdaapproves #fdaapproved #cancertherapy
Not just this day, but every day, we're celebrating powerful women around the globe and remind everyone that #equality is key for a healthy world. Happy International Women's Day!
We're powerful together!
#womensupportingwomen #mensupportingwomen #peoplesupportingpeople #kadınlargünümüzkutluolsun #kadinlargünü #weltfrauentag #eşitlik #gleichberechtigung #felizdiadelamujer #felizdiadamulher #giornatainternazionaledelladonna #смеждународнымженскимднем #uguaglianza #igualdade #igualdad
On February 26, 2021 the Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma.
Learn more about myeloma and multiple myeloma treatments on our website: canceredinstitute.org/myeloma-treatments
Learn more about myeloma and multiple myeloma on our website: canceredinstitute.org/myeloma
If you need help for your cancer treatment and care, apply to our CERI Personalized Patient Program™: canceredinstitute.org/patient-program
#fdaapproval #FDA #multiplemyeloma #myeloma #multiplemyelomatreatment #multiplemyelomaawareness #myelomaawareness #MyelomaAwarenessMonth
We have been waiting for this approval!
The US Food and Drug Administration (FDA) has finally approved Bristol Myers Squibb’s (BMS) CAR T-cell therapy Breyanzi, previously known as liso-cel, on February 5, 2021, after delaying the decision in November 2020.
Breyanzi (lisocabtagene maraleucel) is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL).
Like the two prior approved CAR-T cell therapies, Breyanzi targets the CD19 protein, which is highly expressed on the surface of B cells and which remains there following the transformation of these cells from normal to malignant.
In February 2020, the FDA began a priority review of Breyanzi in LBCL, but later delayed its decision on the CAR T therapy after it was unable to complete an inspection of a third-party manufacturing facility in the US. The FDA cited travel restrictions due to the COVID-19 pandemic to conduct the inspection.
Breyanzi is originally a Celgene product. BMS acquired Celgene in 2019 for $74bn, and the CAR-T therapy is one of the key assets critical to the potential payout of the merger.
There are now three approved CAR T therapies:
Of the 192 patients evaluable for response:
Cytokine release syndrome (CRS) and toxicity are side effects seen in CAR-T cell therapies.
FDA approved lisocabtagene maraleucel with a Risk Evaluation and Mitigation Strategy because of the risk of fatal or life-threatening CRS and neurologic toxicities.
The recommended regimen is a single dose containing 50 to 110 x 106 CAR-positive viable T cells with a 1:1 ratio of CD4 and CD8 components, administered by IV infusion and preceded by fludarabine and cyclophosphamide for lymphodepletion.
February is Black History Month!
As more and more disparities in healthcare is being talked about in the news and among health institutions, we at Cancer Education and Research Institute® are proud to having built our organization in 2013 on the base of healthcare inclusion and equity for ALL. Starting from our early days, we’ve served many patients from various countries in Africa and had strong representation in our board of director. We are proud to be one of the leaders in healthcare diversity, equity, and inclusion.
To learn more about us, visit http://canceredinstitute.org, and if you’d like to join us, please visit:
Black History Month is an annual celebration of achievements by African Americans and a time for recognizing their central role in U.S. history. Also known as African American History Month, the event grew out of “Negro History Week,” the brainchild of noted historian Carter G. Woodson and other prominent African Americans. Since 1976, every U.S. president has officially designated the month of February as Black History Month. Other countries around the world, including Canada and the United Kingdom, also devote a month to celebrating Black history.
The Black History Month 2021 theme, “Black Family: Representation, Identity and Diversity” explores the African diaspora, and the spread of Black families across the United States.
#BlackHistoryMonth #blackhistorymonth2021 #blackhistory #africanamerican #blackcommunities #blacklivesmatter #healthcareequity #healthcaredisparities #healthcare #racialjustice #science #medicine #blackcommunities #healthcareforall #racialequality
Dr. Martin Luther King, Jr. was one of the most powerful leaders in the human history. A leader who changed the world, a leader who made a difference for all, who fought for equality and justice. We surely should to celebrate him not once a year, but throughout the year!
About Dr. Martin Luther King, Jr:
In the eleven-year period between 1957 and 1968, King traveled over six million miles and spoke over twenty-five hundred times, appearing wherever there was injustice, protest, and action; and meanwhile he wrote five books as well as numerous articles. In these years, he led a massive protest in Birmingham, Alabama, that caught the attention of the entire world, providing what he called a coalition of conscience. and inspiring his “Letter from a Birmingham Jail”, a manifesto of the Negro revolution; he planned the drives in Alabama for the registration of Negroes as voters; he directed the peaceful march on Washington, D.C., of 250,000 people to whom he delivered his address, “l Have a Dream”, he conferred with President John F. Kennedy and campaigned for President Lyndon B. Johnson; he was arrested upwards of twenty times and assaulted at least four times; he was awarded five honorary degrees; was named Man of the Year by Time magazine in 1963; and became not only the symbolic leader of American blacks but also a world figure.
At the age of thirty-five, Martin Luther King, Jr., was the youngest man to have received the Nobel Peace Prize. When notified of his selection, he announced that he would turn over the prize money of $54,123 to the furtherance of the civil rights movement.
On the evening of April 4, 1968, while standing on the balcony of his motel room in Memphis, Tennessee, where he was to lead a protest march in sympathy with striking garbage workers of that city, he was assassinated.
- Reference: Nobelprize.org